MetaStat Inks Agreements for Epithelial Cancer Biomarkers | GenomeWeb

NEW YORK (GenomeWeb News) – MetaStat today said it has reached two exclusive licensing agreements for the use of alternatively spliced mRNA and protein isoform biomarkers.

The agreements are with the Massachusetts Institute of Technology and its David H. Koch Institute for Integrative Cancer Research at MIT and its department of biology, the Albert Einstein College of Medicine of Yeshiva University, and Montefiore Medical Center. The technology being licensed is for the diagnosis, prognosis, and treatment of metastasis in epithelial solid tumor cancers.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: role for RNA splicing in genetic variation, and more.

An advocacy group sues the US Food and Drug Administration over redactions of information about advisory committee members, Stat News reports.

Mexico is trying to lure young genomics researchers back home with their own labs, Science reports.

A molecular autopsy has aided a woman's search for why sudden cardiac death has stalked her family, the Wall Street Journal reports.